PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: concordance among 3 commonly used and commercially available antibodies
H Reis, R Serrette, J Posada, V Lu… - The American journal …, 2019 - journals.lww.com
The introduction of immune checkpoint blockade (ICB) therapy has transformed the
management of advanced bladder cancer (BC). Despite its limitations, PD-L1
immunohistochemistry may serve as a predictive biomarker of anti-PD-L1/PD1 therapy.
While urothelial carcinoma (UC) patients with predominant or pure variant histology (UCV)
account for up to one-third of advanced cases, to date, most ICB BC studies have excluded
patients with such histologies. To assess the potential utility of ICB in patients with UCV, we …
management of advanced bladder cancer (BC). Despite its limitations, PD-L1
immunohistochemistry may serve as a predictive biomarker of anti-PD-L1/PD1 therapy.
While urothelial carcinoma (UC) patients with predominant or pure variant histology (UCV)
account for up to one-third of advanced cases, to date, most ICB BC studies have excluded
patients with such histologies. To assess the potential utility of ICB in patients with UCV, we …
